Biotech
Freenome
Freenome raises $270M Series C at $1.1B valuation
South San Francisco, CAFebruary 9, 20211 min read
Total Raised
$270M
Valuation
$1.1B
Latest Round
Series C
Employees
300+
Freenome: Series C Funding Round
Freenome has successfully raised $270M in Series C funding, reaching a valuation of $1.1B.
Company Overview
Early cancer detection using AI
Funding Details
The Series C round was led by T. Rowe Price, with participation from Perceptive Advisors.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- T. Rowe Price: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
Company Info
Headquarters
South San Francisco, CA
Founded
2014
Team Size
300+
Last Round
$270M(Feb 2021)
Investors (2)
T
T. Rowe PriceLeadLead Investor
Verified investor in Series C
P
Perceptive AdvisorsInvestor
Verified investor in Series C
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free